ACADIA Pharmaceuticals (MEX:ACAD) Marketable Securities: MXN10,265 Mil (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
74 GF Score
Price MXN460.00
GF Value MXN496.85
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Marketable Securities?

ACADIA Pharmaceuticals MEX:ACAD 74 Marketable Securities is MXN10,265 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 74/100 and a GF Value™ of MXN496.85 (Fairly Valued). The stock has 10 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. ACADIA Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was MXN10,265 Mil.

ACADIA Pharmaceuticals's annual Marketable Securities increased from Dec. 2023 (MXN4,247 Mil) to Dec. 2024 (MXN9,102 Mil) and increased from Dec. 2024 (MXN9,102 Mil) to Dec. 2025 (MXN11,559 Mil).

ACADIA Pharmaceuticals  (MEX:ACAD) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

ACADIA Pharmaceuticals Marketable Securities Related Terms

ACADIA Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Marketable Securities Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,657.28 5,887.34 4,247.09 9,101.51 11,559.50

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,490.17 9,571.99 10,805.16 11,559.50 10,265.04
MEX:ACAD
74GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of MXN10,265 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Marketable Securities of MXN10,265 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Marketable Securities too high?
ACADIA Pharmaceuticals' current Marketable Securities is MXN10,265 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Marketable Securities compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Marketable Securities of MXN10,265 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Marketable Securities is MXN10,265 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN496.85, compared to a current price of MXN460.00 — trading 7.4% below its estimated fair value. The current Marketable Securities is MXN10,265 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 74/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Marketable Securities is MXN10,265 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of MXN460.00 is trading 7.4% below its estimated GF Value™ of MXN496.85. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Marketable Securities: MXN10,265 Mil
  • GF Value™: MXN496.85 vs. price of MXN460.00 (7.4% below fair value)
  • GF Score™: 74/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
74GF Score

Get the complete analysis for MEX:ACAD

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN460.00
Price
MXN496.85
GF Value